A total of 1678 consecutive patients who had biopsy proven prostate cancer and underwent RP with postoperative Gleason score (GS) of 7 were retrospectively reviewed. The patients were then divided into 4 groups:
1. upgraded GS 3+4
2. non-upgraded GS 3+4
3. upgraded GS 4+3
4. non-upgraded GS 4+3
Kaplan-Meier survival curve and multivariable models were developed to examine the influence of pathological upgrading of GS 7 on the risk of biochemical recurrence.
Mean age of the non-upgraded GS 4+3 was significantly higher than other groups. Five year biochemical recurrence free survival rate was 85%, 73%, 69% and 60% in the 4 groups, respectively. No significant difference was found between group 2 and group 3.
The authors concluded that that the information on pathologic upgrading could help provide more detailed information on the risk of biochemical recurrence in GS 7 disease.
Presented by: Cho MH
Affiliation: Medical Center, Seoul, South Korea
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal